Alfa Synucleïne N-terminaal Antilichaam, Kloon 11D4: RPE

Alpha-synuclein is a presynaptic neuronal protein implicated in the pathogenesis of several neurodegenerative diseases, including Parkinson’s disease and dementia with Lewy bodies. Among its structural domains, the N-terminal region plays a pivotal role in membrane binding, conformational dynamics, and aggregation behavior. Post-translational modifications, particularly C-terminal truncations, significantly influence alpha-synuclein’s aggregation propensity and neurotoxicity (1) . C-terminally truncated alpha-synuclein species are highly enriched in pathological inclusions such as Lewy bodies and Lewy neurites. These truncated forms exhibit accelerated fibrillization and enhanced prion-like propagation in cellular and animal models of Parkinson’s disease, underscoring their pathogenic relevance (1) . Importantly, such truncations can alter the structural conformation of alpha-synuclein, masking epitopes commonly targeted by antibodies, including those recognizing phosphorylated serine 129 (pSer129) . This epitope masking has critical implications for research and diagnostics. Antibodies specific to pSer129 may fail to detect C-terminally truncated alpha-synuclein, potentially underestimating the burden of pathogenic species in tissue samples. Therefore, careful selection of antibodies that target the N-terminal region is essential for accurate detection and quantification of disease-relevant alpha-synuclein conformers (3) . Understanding the structural and functional roles of the alpha-synuclein N-terminus is vital for elucidating disease mechanisms and developing targeted therapeutic strategies in synucleinopathies.

Mouse Anti-Human Alpha Synuclein N-terminal Monoclonal IgG1

Alpha Synuclein, α-Synuclein, SNCA, alphaSYN, NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Synuclein alpha, Synuclein alpha 140, Synuclein, alpha (non A4 component of amyloid precursor), isoform NACP140, PARK1, PARK 1, PARK4, PARK 4, Parkinson disease familial 1, Parkinson disease (autosomal dominant, Lewy body) 4, SYN, SYUA_HUMAN

12352203

Non-hazardous

Non-hazardous

6622

P37840

P37840

Alpha synuclein aa 1-20

11D4

RPE

CNS and peripheral nerves

Monoclonal

WB | IHC

Neuroscience | Neurodegeneration | Alzheimer's Disease | Tangles & Tau | Neuroscience | Neurodegeneration | Parkinson's Disease | Synuclein | Neuroscience | Neurodegeneration | Multiple System Atrophy

Protein G Purified

A 1:1000 dilution was sufficient for detection of Alpha Synuclein in rodent brain lysates in WB and 1:100 dilution on human brain tissue (Parkinson’s) in IHC.

1mg/ml

WB (1:1000), IHC (1:100) ; optimal dilutions for assays should be determined by the user.; optimal dilutions for assays should be determined by the user.

95.46mM Phosphate, 2.48mM MES and 2mM EDTA

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

Blue Ice or 4ºC

-20ºC

https://www.stressmarq.com/wp-content/uploads/Antibody-MSDS.pdf

Detects the N-terminal region of alpha synuclein

1. Mahul-Mellier, A.-L., Altay, M. F., Maharjan, N., et al. (2024) . Dissecting the differential role of C-terminal truncations in the regulation of aSyn pathology formation and the biogenesis of Lewy bodies. bioRxiv. DOI: 10.1101/2024.11.29.625993 2. Bell, R., Vendruscolo, M. (2021) . Modulation of the interactions between α-synuclein and lipid membranes by post-translational modifications. Frontiers in Neurology, 12, 661117. DOI: 10.3389/fneur.2021.661117 3. Iyer, A., Roeters, S. J., Kogan, V., Woutersen, S., Claessens, M. M. A. E., & Subramaniam, V. (2017) . C-Terminal Truncated α-Synuclein Fibrils Contain Strongly Twisted β-Sheets. Journal of the American Chemical Society, 139 (43), 15392-15400. DOI: 10.1021/jacs.7b07403

Human | Mouse | Rat

Cytoplasm; membrane-bound to vesicles in neurons

IgG1

Human